Precedential and Key Federal Circuit Opinions - 1. ENANTA PHARMACEUTICALS, INC v. PFIZER INC. (2025-1427, 6/23/2026) (Lourie, ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Viatris Inc. hits a 52-week high, driven by a strong late-stage pipeline, but shares corrected on Effexor sales decline.

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage China’s fast early ...

Jonathan is the deputy corporate editor at The Wall Street Journal, helping manage a team of reporters and editors who cover industries ranging from autos and airlines to retailers, food makers and ...

SPRINGFIELD, Mo. (KY3) - If you use an EpiPen, you might be able to get $90 from a class-action lawsuit. The lawsuit claims Mylan conspired with Pfizer and Teva to suppress the release of generic ...

$10.4 billion invested in internal research and development projects, and Approximately $8.8 billion invested in business development transactions, primarily reflecting the Metsera acquisition and the ...

That's the good news. The bad news is that while Pfizer "beat" on both sales and adjusted earnings, its earnings as calculated according to generally accepted accounting principles (GAAP) showed a ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy. By Francesca Regalado The obesity drug developer ...

This earnings decrease was mainly driven by a one-time acquired in-process research and development charge related to Pfizer's licensing deal with 3SBio (TRSBF +10.00%). Without the impact of this ...